Last $3.70 USD
Change Today +0.45 / 13.85%
Volume 18.4M
GERN On Other Exchanges
Symbol
Exchange
Frankfurt
As of 8:10 PM 11/21/14 All times are local (Market data is delayed by at least 15 minutes).

geron corp (GERN) Snapshot

Open
$3.30
Previous Close
$3.25
Day High
$3.76
Day Low
$3.28
52 Week High
12/6/13 - $6.54
52 Week Low
03/12/14 - $1.31
Market Cap
581.7M
Average Volume 10 Days
9.4M
EPS TTM
$-0.25
Shares Outstanding
157.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for GERON CORP (GERN)

geron corp (GERN) Related Businessweek News

No Related Businessweek News Found

geron corp (GERN) Details

Geron Corporation, a clinical stage biopharmaceutical company, develops a telomerase inhibitor, imetelstat, to treat hematologic myeloid malignancies. The company was founded in 1990 and is based in Menlo Park, California.

46 Employees
Last Reported Date: 03/17/14
Founded in 1990

geron corp (GERN) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $569.3K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $330.0K
Executive Vice President of Development and T...
Total Annual Compensation: $367.4K
Executive Vice President of Legal Affairs & H...
Total Annual Compensation: $302.2K
Executive Vice President of Business Developm...
Total Annual Compensation: $341.6K
Compensation as of Fiscal Year 2013.

geron corp (GERN) Key Developments

Geron Corporation Enters into License Agreement with Janssen Biotech to Develop Cancer Drug

Geron Corporation has entered into an exclusive worldwide license and collaboration agreement with Janssen Biotech Inc. to develop and commercialize, imetelstat, Geron's telomerase inhibitor product candidate, for oncology, including hematologic malignancies, and other human therapeutics uses. Under the terms of the agreement, Geron will receive an initial payment of $35 million due after the applicable waiting periods under the Hart-Scott Rodino Act and is eligible to receive additional payments up to a potential total of $900 million for the achievement of development, regulatory and commercial milestones, as well as royalties on worldwide net sales. Certain regulatory, development, manufacturing and promotional activities will be managed through a joint governance structure, with Janssen responsible for operational implementation of these activities.

Geron Corporation, Janssen Biotech, Inc. - Special Call

Geron Corporation, Janssen Biotech, Inc. - Special Call

Geron Corporation Presents at Stifel Healthcare Conference 2014, Nov-19-2014 01:50 PM

Geron Corporation Presents at Stifel Healthcare Conference 2014, Nov-19-2014 01:50 PM. Venue: The Palace Hotel, 455 Madison Ave, New York, NY 10022, United States. Speakers: John A. Scarlett, Chief Executive Officer, President and Director.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GERN:US $3.70 USD +0.45

GERN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Biorestorative Therapies Inc $0.36 USD +0.0005
BioTime Inc $3.11 USD -0.19
IntelliCell BioSciences Inc $0.0002 USD 0.00
Neuralstem Inc $2.78 USD -0.02
ReNeuron Group PLC 3.38 GBp +0.125
View Industry Companies
 

Industry Analysis

GERN

Industry Average

Valuation GERN Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GERON CORP, please visit www.geron.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.